

Western Australian Immunisation Schedule

Childhood

Age and eligibility	Antigen/Antibody	Brand(s)	Important information
Birth to <7 days	Nirsevimab	Beyfortus®	Babies born 1/5/24 to 30/9/24
	Hepatitis B	H-B-Vax® II Paed or Engerix® B Paed	
6-8 weeks	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
	13vPCV	Prevenar® 13	
	Rotavirus	Rotarix®	Oral dose 1: Must be given by 14 weeks of age
Aboriginal* and/or MRC	MenACWY	Nimenrix®	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
4 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
	13vPCV	Prevenar® 13	
	Rotavirus	Rotarix®	Oral dose 2: Must be given by 24 weeks of age
Aboriginal* and/or MRC	MenACWY	Nimenrix®	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
6 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
	13vPCV	Prevenar® 13	
MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
12 months	MenACWY	Nimenrix®	
	MMR	MMRII® or Priorix®	
	13vPCV	Prevenar® 13	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
MRC	Hepatitis B	H-B-Vax® II Paed or Engerix® B Paed	<32 weeks gestation or <2000g birth weight
18 months	DTPa	Infanrix® or Tripacel®	
	Hib	ActHIB®	
	MMRV	Priorix-Tetra® or ProQuad®	Do not administer MMRV as dose 1 of a measles-containing vaccine if <4 years of age
Aboriginal	Hepatitis A	Vaqa® Paed/Adol	Dose 1 of 2. Dose 2 to be administered at least 6 months after dose 1
<2 years	Catch-up for MenB is available for Aboriginal children <2 years of age		
Aboriginal			
4 years	DTPa-IPV	Quadracel® or Infanrix® IPV	
	Hepatitis A	Vaqa® Paed/Adol	Not required if previously received 2 doses (first dose at age ≥12 months) at least 6 months apart
Aboriginal and/or MRC	23vPPV	Pneumovax23®	Dose 1 (if not previously administered). Dose 2 should be administered at least 5 years later

Respiratory Syncytial Virus (RSV)

Age and eligibility	Antigen/Antibody	Brand(s)	Important information
Babies born from 1/10/23 to 30/09/24 All Aboriginal children born from 1/10/22 to 30/09/24 Children with certain MRC born from 1/10/22 to 30/09/23	Nirsevimab	Beyfortus®	<p>Dosage:</p> <p>For babies aged younger than 8 months of age including MRC: dosage is determined by weight (50mg for infants <5kg and 100mg for infants ≥5kg).</p> <p>For children aged 8 months and older including MRC (regardless of weight): dosage is 200 mg (2x100mg doses)</p> <p>For the list of medical risk conditions please see Respiratory Syncytial Virus (RSV) immunisation</p>

Adolescent and adult

Age and eligibility	Antigen	Vaccine brand(s)	Important information
Year 7	HPV	Gardasil®9	Catch-up for adolescents <26 years of age
	dTpa	Boostrix® or Adacel®	
Year 10	MenACWY	Nimenrix®	
≥18 years MRC	Herpes-zoster	Shingrix®	2 doses, given 1–2 months apart
Pregnant	dTpa	Boostrix® or Adacel®	Each pregnancy, ideally between 20–32 weeks
≥20 years Aboriginal*	Hepatitis B	Engerix® B	For non-immune persons. See the Australian Immunisation Handbook for recommendations and timing of doses
Adult refugees and humanitarian entrants	dTpa (Boostrix® or Adacel®), HepB (H-B-Vax® II or Engerix® B), IPV (IPOL®), MMR (MMRII® or Priorix®), VZV (Varivax®). HPV (Gardasil®9) <26 years of age		See the Australian Immunisation Handbook for timing of doses
≥50 years Aboriginal	13vPCV 23vPPV	Prevenar® 13 Pneumovax23®	See the Australian Immunisation Handbook for timing of doses
	Herpes-zoster	Shingrix®	2 doses, given 2–6 months apart
Born after 1965*	MMR	Priorix®	Give 1 or 2 doses as required. Whilst serology is not routinely recommended, see WA adult measles vaccination program for details.
≥65 years	Herpes-zoster	Shingrix®	2 doses, given 2–6 months apart
≥70 years	13vPCV	Prevenar® 13	

All individuals diagnosed with **specified MRC** aged >12 months of age require 1 dose of 13vPCV at diagnosis, followed by a first dose of 23vPPV, 2 to 12 months later or at 4 years of age, whichever is later. A second dose is given at least 5 years later

Additional *Haemophilus influenzae* type b (Hib), meningococcal and pneumococcal vaccines are recommended for people with specified risk conditions. Refer to the [Australian Immunisation Handbook](#) for details

Age and eligibility	Vaccine brand(s)	Important information
6 Months to <5 Years	Vaxigrip®Tetra, Fluarix® Tetra	For children <9 years or persons with MRC, 2 doses required 1 month apart in the first year they receive influenza vaccine. One dose annually in subsequent years.
≥5 Years to Year 6*	FluQuadri®	
5 Years to <65 Years	Vaxigrip®Tetra, Fluarix®Tetra, Flucelvax®Quad	For information on specified MRC see Australian Immunisation Handbook or annual ATAGI advice on seasonal influenza vaccines
Aboriginal and/or MRC		
Vulnerable cohorts* 12 to <65 Years	FluQuadri®	For non-NIP eligible residents in congregate living and people experiencing homelessness.
Pregnancy	Vaxigrip®Tetra, Fluarix®Tetra, Flucelvax®Quad	Each pregnancy, any trimester
All West Australians 12 to <65 years*	FluQuadri®	Eligibility under Free Influenza Program May and June 2024
≥65 Years	Fluad® Quad	Preferentially use adjuvanted QIV
WA Health staff^*	Fluarix® Tetra, FluQuadri®	For ≥65 years use Fluad® Quad

*Refers to WA State-funded Programs.

^Refers to all persons attending WA Health staff influenza vaccination services.

The term **'Aboriginal'** is inclusive of all Aboriginal and Torres Strait Islander people.

MRC refers to people with medical risk conditions. Refer to the current online edition of the [Australian Immunisation Handbook](#) for all medical risk conditions, recommendations and timing of doses.

Persons aged <20 years can catch-up scheduled vaccines, refer to [Australian Immunisation Handbook](#) for timing of doses.